Literature DB >> 8988066

Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes.

F Thalhammer1, S Schmaldienst, I Elmenyawi, M Atteneder, H Burgmann, U Hollenstein, A Georgopoulos, W Graninger, D Putz, A R Rosenkranz, G Mayer, W H Hörl, S Breyer.   

Abstract

Cefpirome is a cephalosporin eliminated primarily by kidneys that requires dosage reduction in patients with renal failure. The pharmacokinetic parameters were studied in 10 patients with end-stage renal disease who were receiving hemodialysis. Repeated intravenous administration of 2 gm cefpirome three times a week resulted in trough levels of 12.2 +/- 5.4 micrograms/ml and peak serum concentrations of 99.6 +/- 82.1 micrograms/ml. After 3 1/2 hours of hemodialysis with polysulfone high-flux membranes, 62.3% +/- 23.3% of cefpirome was removed. The interdialytic half-life was 9.35 +/- 0.99 hours, and the intradialytic half-life was 2.02 +/- 0.7 hours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8988066     DOI: 10.1016/S0009-9236(96)90212-X

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan; Jarurat Punyo
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration.

Authors:  Matthias G Vossen; Klaus-Bernhard Gattringer; Walter Jäger; Stefanie Kraff; Florian Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

3.  Doripenem Treatment during Continuous Renal Replacement Therapy.

Authors:  M G Vossen; J M Wenisch; A Maier-Salamon; A Fritsch; K Saria; C Zuba; S Jilch; R Lemmerer; M Unger; U Jaehde; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.

Authors:  M G Vossen; L Ehmann; S Pferschy; A Maier-Salamon; M Haidinger; C Weiser; J M Wenisch; K Saria; C Kajahn; S Jilch; R Lemmerer; M Bécède; M Zeitlinger; C Kloft; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.

Authors:  F Thalhammer; P Schenk; H Burgmann; I El Menyawi; U M Hollenstein; A R Rosenkranz; G Sunder-Plassmann; S Breyer; K Ratheiser
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 6.  Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.

Authors:  F Thalhammer; W H Hörl
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.